Category Uncategorized

Sofosbuvir+Ledipasvir FDC generic market prices in India 26th of April 2016

FDA has low efficacy threshold for approving cancer medicines

How the MDGs gave up on measuring access to medicines

Examples of enormous price raises of old drugs

IFPMA’s incoming president quoted by Lilly saying there is no evidence that patents affect A2M

Cases of UK government using compulsory licenses

Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical Patents

-Secondary patent claims are extremely common (more common than chemical compound patent claims), and have a significant effect on the patent-life of drugs -TRIPS does require member countries to adopt patent protection, but these requirements are general and do not mention secondary patents (reference number 21: Harmonization and Its Discontents: A Case Study of TRIPS Implementation in […]

Indian Intellectual Property: Time For A Legal (WTO) Complaint?

article of November 2013 after the rejection (april 2013) of the patent application of Glivec (Novartis) and the ‘compulsory licensing’ of (Nexavar from Bayer): -a US government lawyer alledges, that it might be about time ‘…for an international legal complaint against India for its disregard of corporate intellectual property…’ -the U.S. Chamber of Commerce ranks India as “…worst among […]